1. Home
  2. AVDL vs JBGS Comparison

AVDL vs JBGS Comparison

Compare AVDL & JBGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVDL
  • JBGS
  • Stock Information
  • Founded
  • AVDL 2015
  • JBGS 2016
  • Country
  • AVDL Ireland
  • JBGS United States
  • Employees
  • AVDL N/A
  • JBGS N/A
  • Industry
  • AVDL Biotechnology: Pharmaceutical Preparations
  • JBGS Real Estate Investment Trusts
  • Sector
  • AVDL Health Care
  • JBGS Real Estate
  • Exchange
  • AVDL Nasdaq
  • JBGS Nasdaq
  • Market Cap
  • AVDL 1.4B
  • JBGS 1.4B
  • IPO Year
  • AVDL 1996
  • JBGS 2017
  • Fundamental
  • Price
  • AVDL $14.54
  • JBGS $21.45
  • Analyst Decision
  • AVDL Strong Buy
  • JBGS Sell
  • Analyst Count
  • AVDL 7
  • JBGS 2
  • Target Price
  • AVDL $19.86
  • JBGS $16.00
  • AVG Volume (30 Days)
  • AVDL 1.4M
  • JBGS 1.1M
  • Earning Date
  • AVDL 08-07-2025
  • JBGS 10-28-2025
  • Dividend Yield
  • AVDL N/A
  • JBGS 3.26%
  • EPS Growth
  • AVDL N/A
  • JBGS N/A
  • EPS
  • AVDL N/A
  • JBGS N/A
  • Revenue
  • AVDL $221,075,000.00
  • JBGS $513,301,000.00
  • Revenue This Year
  • AVDL $63.77
  • JBGS N/A
  • Revenue Next Year
  • AVDL $29.91
  • JBGS $2.33
  • P/E Ratio
  • AVDL N/A
  • JBGS N/A
  • Revenue Growth
  • AVDL 132.35
  • JBGS N/A
  • 52 Week Low
  • AVDL $6.38
  • JBGS $13.28
  • 52 Week High
  • AVDL $16.66
  • JBGS $22.45
  • Technical
  • Relative Strength Index (RSI)
  • AVDL 70.53
  • JBGS 66.41
  • Support Level
  • AVDL $14.52
  • JBGS $20.20
  • Resistance Level
  • AVDL $14.99
  • JBGS $20.96
  • Average True Range (ATR)
  • AVDL 0.53
  • JBGS 0.50
  • MACD
  • AVDL -0.00
  • JBGS 0.05
  • Stochastic Oscillator
  • AVDL 63.55
  • JBGS 99.75

About AVDL Avadel Pharmaceuticals plc

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.

About JBGS JBG SMITH Properties

JBG SMITH Properties is a real estate investment trust based in the United States. It owns, operates, invests in, and develops real estate assets concentrated in amenity-rich, metro-served submarkets in and around Washington, DC. In addition, the company also provides fee-based real estate services to legacy funds through its third-party real estate services business. The operating segments of the company are commercial, multifamily, and third-party asset management and real estate services. It generates maximum revenue from the commercial segment.

Share on Social Networks: